EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

Smolen, J.S.; Landewe, R.; Breedveld, F.C.; Buch, M.; Burmester, G.; Dougados, M.; ... ; Heijde, D. van der (2014)

Article / Letter to editor

• Rheumatoid Arthritis
• DMARDs (synthetic)
• DMARDs (biologic)
• Treatment
• Early Rheumatoid Arthritis

• All authors: Smolen, J.S.; Landewe, R.; Breedveld, F.C.; Buch, M.; Burmester, G.; Dougados, M.; Emery, P.; Gaujoux-Viala, C.; Gossec, L.; Nam, J.; Ramiro, S.; Winthrop, K.; Wit, M. de; Aletaha, D.; Betteridge, N.; Bijlsma, J.W.J.; Boers, M.; Buttgereit, F.; Combe, B.; Cutolo, M.; Damjanov, N.; Hazes, J.M.W.; Kouloumas, M.; Kvien, T.K.; Mariette, X.; Pavelka, K.; Riel, P.L.C.M. van; Rubbert-Roth, A.; Scholte-Voshaar, M.; Scott, D.L.; Sokka-Isler, T.; Wong, J.B.; Heijde, D. van der
• Date: 2014-03-31
• Journal: Annals of the Rheumatic Diseases
• Volume: 73
• Issue: 3
• Pages: 492 - 509
• DOI: doi:10.1136/annrheumdis-2013-204573